WilmerHale Webinar: Deciphering the New FDA Reform Legislation - What the FDA Amendments Act of 2007 Means for Research-Based Pharmaceutical Companies (Session One)

Name: WilmerHale Webinar: Deciphering the New FDA Reform Legislation - What the FDA Amendments Act of 2007 Means for Research-Based Pharmaceutical Companies (Session One)
Start: 2007-10-17
End: 2007-10-17

2007-10-17

Speaking Engagement

This WilmerHale webinar series is designed to provide pharmaceutical companies with a detailed overview of the new Food & Drug Administration Amendments Act of 2007, a forecast of its impact on all aspects of regulatory compliance and product development, as well as practical tips to prepare for implementation of the new regulatory requirements. This first session will offer an overview of the new drug provisions of FDAAA and will also address the competitive impact of FDAAA on exclusivities and the Citizen Petition process.